Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Disruptive Innovation in Dialysis and Medical Device Manufacturing

Disruptors come in many flavors and innovate countless industries. Healthcare is one space that welcomes technology disruption, where advancements in medical devices can improve the lives of many. Outset Medical is one such medical device manufacturer seeking to transform the dialysis experience. Marc Nash, VP of Manufacturing at Outset Medical, joined DisruptED’s Ron Stefanski…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Promoted content from DisruptED on MarketScale.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Request an invite

Disruptors come in many flavors and innovate countless industries. Healthcare is one space that welcomes technology disruption, where advancements in medical devices can improve the lives of many. Outset Medical is one such medical device manufacturer seeking to transform the dialysis experience.

Marc Nash, VP of Manufacturing at Outset Medical, joined DisruptED’s Ron Stefanski to share his company’s exciting work to improve the dialysis process and experience. A dialysis patient must endure a cumbersome lifelong process that creates a burden for them and their family, not to mention the physical toll it carries on the body.

“We wanted to see how we could give patients back their life,” Nash said. “How could they take more control over what they could do? So, we created a product called Tablo, and we’re now in the home market.”

Making dialysis available in a patient’s home is a critical first step in that journey to give patients their freedom back. With a typical dialysis treatment taking five hours and up to three times a week, not traveling to a healthcare facility to get treatment can be a game-changer.

“Imagine if you wanted to do dialysis at 7 p.m. to 10 p.m. or 11 p.m., most clinics are not going to be open during these times,” Nash said. “Where if you’re in the comfort of your house, you can go to work, take care of the kids, and then go about your dialysis.”

Nash said it comes down to the people within Outset Medical to make strides in dialysis.

“When I hire within my organization, I’m looking for attitude. I want to see the people that have grit and determination. Most people are not going to come to my organization knowing dialysis; they’re going to come from either the Medtech space, aerospace, they’re going to come from automotive, or tech, and I’m going to have to teach them dialysis. That’s the easy part. What’s hard to teach is grit.”

DisruptED

Part of this channel

DisruptED

Education, workforce, and manufacturing futures with Ron J. Stefanski.

Visit the channel

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.

Follow Healthcare Insights

Get new expert content in your inbox.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

Tarsus’ $450M Alkeus deal puts phase 3 retina programs on the same integration plan

Tarsus’ $450M Alkeus deal puts phase 3 retina programs on the same integration plan

Tarsus has made a $450 million deal with Alkeus to acquire two assets, including a phase 3 oral Stargardt program and a post-injection antiseptic. The focus now moves to clinical trial operations, chemistry manufacturing and controls, and plans for specialty distribution. These acquisitions aim to expand Tarsus' retina programs.

  • 01Tarsus acquired a phase 3 oral Stargardt asset and a post-injection antiseptic for $450 million.
  • 02The acquisitions focus on enhancing clinical trial operations and chemistry manufacturing controls.
  • 03Plans for future specialty distribution of the acquired assets are in place.

Aug 29, 2026

FDA’s Oct. 19 AI docket forces medtech teams to write tests, not slide decks

FDA’s Oct. 19 AI docket forces medtech teams to write tests, not slide decks

The FDA has released a generative AI discussion paper proposing a shift towards competency-style evaluation and increased postmarket monitoring in the healthcare industry. This move may lead vendors and hospital buyers to prioritize developing robust testing protocols for AI applications. The focus is on ensuring reliable and safe AI implementation in medical technologies.

  • 01The FDA's discussion paper suggests implementing competency-style evaluation for AI in healthcare.
  • 02There is an emphasis on increased postmarket monitoring for AI applications in the medical field.
  • 03Vendors and hospital buyers are encouraged to focus on developing testing protocols rather than presentations.

Aug 29, 2026

SILMO Paris 2026 brings smart glasses and AI into the purchasing cycle

SILMO Paris 2026 brings smart glasses and AI into the purchasing cycle

SILMO Paris 2026 is focusing on integrating smart glasses and AI into the purchasing processes for optical retailers and labs. The event is anticipated to attract around 34,000 visitors and feature 950 exhibitors, indicating significant interest in AI imaging workflows and smart-glass innovations. The agenda highlights a future direction towards advanced technology in optical retail and laboratory settings.

  • 01SILMO Paris 2026 will host nearly 34,000 visitors and 950 exhibitors.
  • 02The event focuses on AI imaging workflows and smart-glass innovations for optical retailers and labs.
  • 03Significant interest is shown in integrating advanced technology within optical retail processes.

Aug 29, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512